Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate N-of-1 series in Smith-Magenis syndrome with ADHD symptoms
2020-004053-76Phase 4Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) and Smith-Magenis syndrome (SMS), sponsored by Amsterdam University Medical Center. Primary endpoint: Hyperactivity/inattention subscale of the Strengths and Difficulties Questionnaire. Started Dec 2020; status: terminated.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)Smith-Magenis syndrome (SMS)
Beyond the preview
Go deeper on 2020-004053-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004053-76.